The spike in flu cases over the past month, along with limited supplies of influenza vaccine and Tamiflu across the United States, has led FDA Commissioner Margaret Hamburg to issue guidance to pharmacists and other healthcare providers.
The spike in flu cases over the past month, along with limited supplies of influenza vaccine and Tamiflu across the United States, has led FDA Commissioner Margaret Hamburg to issue guidance to pharmacists and other healthcare providers.
"Some locations may experience intermittent, temporary shortages of the oral suspension form of the anti-viral, Tamiflu, which is the liquid version often prescribed for children, for the remainder of the flu season," FDA Commissioner Hamburg said during a press conference late last week.
“Tamiflu has been reported on the drug shortages list, and some pharmacies have begun compounding liquid dosage Tamiflu to meet demand,” a statement from the National Association of Boards of Pharmacy (NABP) announced.
Meanwhile, FDA has been working with Tamiflu’s manufacturer, Genentech, to increase supply. “I want to assure patients also that Tamiflu 30 mg and 40 mg capsules remain available, and pediatric patients age one and older can be dosed correctly using the 30 mg and 40 mg capsules,” Hamburg said.
Still the rapid spread of influenza this season is alarming. 48 states are reporting widespread flu activity, and the City of Boston recently responded to the upsurge in flu cases by declaring a health emergency.
According to new data from the Centers for Disease Control (CDC), of the 5,249 influenza-associated hospitalizations that have been reported this season, 49.6% have occurred among patients who are aged 65 and older.
In addition, the proportion of deaths attributed to pneumonia and influenza increased sharply for the week of January 6-12, remaining above the “epidemic” threshold for the second consecutive week, the CDC reported.
At the same time, the CDC found that the number of people seeing their healthcare providers for flu-like illnesses decreased from 4.8% to 4.6% for the week of January 6-12, although it remains above the national baseline for the sixth consecutive week. In addition, the number of respiratory specimens testing positive for influenza in the United States dropped to 29.4% for the week of January 6-12, down from 34% the prior week.
For more information or assistance with the flu outbreak, contact RX Response at (866) 247-2694.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.